A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis
Completed · Phase 3 · NCT03738397
Conditions: Atopic Dermatitis
At a glance
- Research payments reported, 2025
- $875
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 673
About the trial
- Sponsor
- AbbVie
- Tested
- Upadacitinib (biological), Dupilumab (biological), Placebo to dupilumab (drug), Placebo to upadacitinib (drug)
- Dates
- Started 2019-02-21; completion 2020-12-09
- Results posted
- Yes
This study will evaluate upadacitinib compared to dupilumab (Dupixent®) in adults with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
From ClinicalTrials.gov, last updated 2024-03-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $875 in research payments for this study in 2025 (1 payments).
Products named: Rinvoq
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Wake Forest University Health Sciences $875
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.